MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Ovid therapeutics Inc

Gesloten

SectorGezondheidszorg

0.54 17.39

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.46

Max

0.56

Belangrijke statistieken

By Trading Economics

Inkomsten

-982K

-10M

Verkoop

54K

130K

Winstmarge

-7,873.077

Werknemers

23

EBITDA

-1.8M

-12M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+489.58% upside

Dividenden

By Dow Jones

Volgende Winsten

12 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

3.3M

28M

Vorige openingsprijs

-16.85

Vorige sluitingsprijs

0.54

Nieuwssentiment

By Acuity

50%

50%

154 / 376 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Ovid therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 jul 2025, 21:01 UTC

Winsten

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 jul 2025, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

18 jul 2025, 20:50 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

18 jul 2025, 20:50 UTC

Marktinformatie
Winsten

Basic Materials Roundup: Market Talk

18 jul 2025, 20:46 UTC

Winsten

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 jul 2025, 20:39 UTC

Acquisities, Fusies, Overnames

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 jul 2025, 20:36 UTC

Winsten

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 jul 2025, 20:16 UTC

Acquisities, Fusies, Overnames

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 jul 2025, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

18 jul 2025, 20:02 UTC

Marktinformatie

Gold Higher to Close Out Week -- Market Talk

18 jul 2025, 19:14 UTC

Marktinformatie

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 jul 2025, 19:06 UTC

Marktinformatie

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 jul 2025, 18:24 UTC

Winsten

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 jul 2025, 18:19 UTC

Winsten

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 jul 2025, 18:11 UTC

Acquisities, Fusies, Overnames

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 jul 2025, 18:11 UTC

Winsten

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 jul 2025, 17:35 UTC

Marktinformatie

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 jul 2025, 16:29 UTC

Marktinformatie

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 jul 2025, 16:28 UTC

Acquisities, Fusies, Overnames

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 jul 2025, 16:22 UTC

Winsten

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 jul 2025, 16:20 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

18 jul 2025, 16:20 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

18 jul 2025, 16:20 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

18 jul 2025, 16:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Energy & Utilities Roundup: Market Talk

18 jul 2025, 16:20 UTC

Marktinformatie
Winsten

Basic Materials Roundup: Market Talk

18 jul 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

18 jul 2025, 16:04 UTC

Winsten

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 jul 2025, 15:58 UTC

Marktinformatie

Global Equities Roundup: Market Talk

18 jul 2025, 15:58 UTC

Marktinformatie

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 jul 2025, 15:47 UTC

Marktinformatie
Winsten

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Peer Vergelijking

Prijswijziging

Ovid therapeutics Inc Prognose

Koersdoel

By TipRanks

489.58% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 2.83 USD  489.58%

Hoogste 4 USD

Laagste 1.5 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ovid therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Technische score

By Trading Central

0.275 / 0.33Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

154 / 376 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.